CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 108 enrolled
Drug / intervention
letrozole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01439711
NCT01439711Phase 2Completed
CompareCT.gov

Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)

Alliance for Clinical Trials in Oncology·interventional·Posted Sep 23, 2011·Updated Mar 27, 2018

In Brief

A Phase 2 clinical trial evaluating letrozole, MRI, and 1 other intervention for Breast Cancer. Completed, enrolled 108 participants across 32 sites.

Detailed Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well letrozole works in treating women with ductal carcinoma in situ.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2011
Enrollment StartFeb 1, 2012
Primary CompletionAug 1, 2016
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.8 years ago

Interventions

letrozoledrug

MRIprocedure

conventional surgeryprocedure